ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 746,24
0,03%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. United Therapeutics Corporation (UTHR)

  7. United Therapeutics Corporation (UTHR) Actualités

UTHR

United Therapeutics (UTHR)

United Therapeutics Corporation
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:UTHR
DateHeureSourceTitreSymboleSociété
31/05/202413h00Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:UTHRUnited Therapeutics Corporation
30/05/202422h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
14/05/202422h10Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
01/05/202412h30Business WireUnited Therapeutics Corporation Reports First Quarter 2024 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
26/04/202420h02Business WireCORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202415h00Business WireUnited Therapeutics Announces World’s First Successful Xenothymokidney TransplantNASDAQ:UTHRUnited Therapeutics Corporation
24/04/202413h00Business WireUnited Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024NASDAQ:UTHRUnited Therapeutics Corporation
16/04/202413h00Business WireUnited Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
26/03/202412h00Business WireUnited Therapeutics Announces the First Comprehensive Review Publication on XenotransplantationNASDAQ:UTHRUnited Therapeutics Corporation
25/03/202412h00Business WireUnited Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase ProgramNASDAQ:UTHRUnited Therapeutics Corporation
05/03/202412h00Business WireUnited Therapeutics Corporation to Present at the Leerink Partners Global Biopharma Conference 2024NASDAQ:UTHRUnited Therapeutics Corporation
27/02/202412h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:UTHRUnited Therapeutics Corporation
27/02/202412h00Business WireUnited Therapeutics Corporation to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
21/02/202412h03Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:UTHRUnited Therapeutics Corporation
21/02/202412h00Business WireUnited Therapeutics Corporation Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
21/02/202411h55Business WireUnited Therapeutics Commences Litigation to Ensure Fairness in the Drug Review ProcessNASDAQ:UTHRUnited Therapeutics Corporation
14/02/202422h57Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:UTHRUnited Therapeutics Corporation
14/02/202412h00Business WireUnited Therapeutics Corporation to Report Fourth Quarter and Full Year 2023 Financial Results Before the Market Opens on Wednesday, February 21, 2024NASDAQ:UTHRUnited Therapeutics Corporation
29/12/202312h00Business WireUnited Therapeutics Corporation to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:UTHRUnited Therapeutics Corporation
22/12/202315h51Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:UTHRUnited Therapeutics Corporation
14/12/202320h06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:UTHRUnited Therapeutics Corporation
13/12/202316h03Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:UTHRUnited Therapeutics Corporation
13/12/202315h15Business WireUnited Therapeutics and Miromatrix Medical Announce Completion of Tender Offer and MergerNASDAQ:UTHRUnited Therapeutics Corporation
12/12/202312h00Business WireUnited Therapeutics and Miromatrix Medical Announce Successful Tender OfferNASDAQ:UTHRUnited Therapeutics Corporation
07/12/202312h00Business WireUnited Therapeutics Named by Newsweek as One of America’s Most Responsible Companies 2024NASDAQ:UTHRUnited Therapeutics Corporation
13/11/202312h06Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:UTHRUnited Therapeutics Corporation
01/11/202321h50Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:UTHRUnited Therapeutics Corporation
01/11/202311h03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:UTHRUnited Therapeutics Corporation
01/11/202311h00Business WireUnited Therapeutics Corporation Reports Third Quarter 2023 Financial ResultsNASDAQ:UTHRUnited Therapeutics Corporation
31/10/202311h05Business WireUnited Therapeutics Announces First Patient Enrolled in Phase 3 TETON PPF Study of Nebulized Tyvaso in Patients with Progressive Pulmonary FibrosisNASDAQ:UTHRUnited Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:UTHR

Dernières Valeurs Consultées

BIT
I05623
Banca IMI
BIT
I06579
Banca Imi
BIT
P1BVT5
BNP Paribas Issuance
LSE
MX75
Corp Andina 31
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés